Search results for "OUTCOME"

showing 10 items of 5148 documents

PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer

2016

This analysis confirms that administering neoadjuvant chemotherapy (NACT) before chemoradiotherapy (CRT) could be a potential option for high-risk, locally advanced rectal cancer. In this setting, MRI tumour regression grade is an independent prognostic factor and, when assessed after NACT, may predict the probability and magnitude of incremental benefit from sequential CRT.EXPERT and EXPERT-C were phase II clinical trials of neoadjuvant chemotherapy (NACT) followed by chemoradiotherapy (CRT) in high-risk, locally advanced rectal cancer (LARC). We pooled individual patient data from these trials. The primary objective was overall survival (OS) in the intention-to-treat (ITT) population. Pro…

AdultMale0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentPopulationPhases of clinical researchKaplan-Meier EstimateDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProgression-free survivalStage (cooking)educationNeoadjuvant therapyAgedAged 80 and overeducation.field_of_studyIntention-to-treat analysisRectal Neoplasmsbusiness.industrySurrogate endpointChemoradiotherapyHematologyMiddle AgedMagnetic Resonance ImagingNeoadjuvant TherapyTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalbusinessChemoradiotherapy
researchProduct

Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma

2018

Long-term oral corticosteroid (OCS) use in patients with severe asthma is associated with significant adverse effects.This 40-week, randomised, double-blind trial evaluated the OCS-sparing potential of tralokinumab in patients with severe, uncontrolled asthma requiring maintenance OCS treatment plus inhaled corticosteroids/long-acting β2-agonists. Overall, 140 patients were randomised to tralokinumab 300 mg or placebo (n=70 in each group) administered subcutaneously every 2 weeks. The primary end-point was percentage change from baseline in average OCS dose at week 40, while maintaining asthma control. Secondary end-points included proportion of patients with a prescribed maintenance OCS do…

AdultMale0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classAdministration OralPlacebolaw.invention03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled trialAdrenal Cortex HormoneslawInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsAdverse effectAgedInhalationRespiratory tract infectionsbusiness.industryAntibodies MonoclonalMiddle AgedAsthmaClinical trialTreatment Outcome030104 developmental biology030228 respiratory systemDisease ProgressionCorticosteroidFemalebusinessTralokinumabEuropean Respiratory Journal
researchProduct

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.

2020

Background: Current availability of several biologic treatments for severe asthma makes it possible to choose the most appropriate for each patient. Sometimes a good percentage of patients with severe asthma may be eligible for biologics that target either the allergic phenotype or the eosinophilic one, but not all respond to that selected as first choice. The aim of our real-life study was to assess whether, for patients with severe eosinophilic allergic asthma, not previously controlled by the anti-IgE omalizumab, the shift to another biologic targeting interleukin-5, such as mepolizumab, may represent a good therapeutic choice. Methods: A total of 41 consecutive patients with severe, per…

AdultMale0301 basic medicinePulmonary and Respiratory Medicinesevere asthmamedicine.medical_specialtyTime FactorsSevere asthmamepolizumab omalizumab severe asthma switchingOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedSeverity of Illness Index03 medical and health sciences0302 clinical medicinereal lifeAnti-Allergic AgentsHumansMedicineswitching.Pharmacology (medical)Anti-Asthmatic AgentsPulmonary EosinophiliaIntensive care medicineLungOriginal ResearchAgedRetrospective Studieslcsh:RC705-779switchingDrug Substitutionbusiness.industrymepolizumablcsh:Diseases of the respiratory systemMiddle AgedAsthmaTreatment Outcome030104 developmental biologyItaly030228 respiratory systemomalizumabFemalebusinessMepolizumabmedicine.drug
researchProduct

Diagnostic genetic screening for assisted reproductive technologies patients with macrozoospermia

2017

International audience; Macrozoospermia is characterized by a high proportion of abnormal spermatozoa with enlarged heads. So far, it has been associated with mutations only in the Aurora Kinase C gene (AURKC) in some cases. Although many publications have reported failure to conceive in couples with macrozoospermia, a few others have described successful pregnancies, thus raising questions as to whether ICSI and AURKC genetic screening should be recommended in all patients with macrozoospermia. First, we report on two monozygotic twins presenting macrozoospermia for whom the genetic status was explored (Aurora Kinase C sequencing) and whole semen and gradient-selected spermatozoa were anal…

AdultMale0301 basic medicineReproductive Techniques Assistedpregnancy outcomesUrologyEndocrinology Diabetes and MetabolismTwinsmenSemenReproductive technologyBiologymedicine.disease_causeAndrologyTeratozoospermia03 medical and health sciences0302 clinical medicineEndocrinologyPolyploidc c.144delc mutationmedicineHumansAurora Kinase CGenetic TestingAurora Kinase C Gene[SDV.GEN]Life Sciences [q-bio]/Geneticsaurora kinase C geneMutationassisted reproductive technologies030219 obstetrics & reproductive medicineurogenital systemtailed spermatozoaGenetic StatusheadSperm3. Good healthmacrozoospermiahuman sperm030104 developmental biologyReproductive Medicinemale-infertilitySperm HeadAurora Kinase Caneuploidy rateflow-cytometry[ SDV.GEN ] Life Sciences [q-bio]/Geneticspolyploid spermatozoaAndrology
researchProduct

Evaluation of the effect of an intervention on the nutritional status of hospitalized patients

2017

Abstract Background and objectives To compare the nutritional status of a population of hospitalized patients, divided into 2 different groups, both at admission and hospital discharge, and to assess the influence of nutritional alteration during the hospital stay. Material and methods Quasi-experimental study comprising 2 groups of patients (N = 581): an intervention group (n = 303), in which nurses received specific training on managing care methodology, and a control group (n = 278), in which nurses continued their usual dynamics. Each group was made up of 2 care units with patients from both surgical and medical specialties. Inclusion criteria: patients admitted to the selected units wi…

AdultMale0301 basic medicineSample selectionPediatricsmedicine.medical_specialtyHospitalized patientsPopulationNutritional Status03 medical and health sciences0302 clinical medicinePatient ageIntervention (counseling)Hospital dischargeHumansMedicineProspective Studies030212 general & internal medicineeducationAgedAged 80 and overeducation.field_of_study030109 nutrition & dieteticsbusiness.industryMalnutritionNutritional statusOdds ratioMiddle AgedHospitalizationNutrition AssessmentTreatment OutcomeFemaleNutrition TherapybusinessFollow-Up StudiesMedicina Clínica (English Edition)
researchProduct

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS

2017

Background: The effect of dimethyl fumarate (DMF) on circulating lymphocyte subsets and their contribution as predictors of clinical efficacy have not yet been investigated in multiple sclerosis (MS). Objective: To evaluate lymphocytes and lymphocyte subsets (analyzed 6 months after DMF start) in MS patients with and without disease activity after 1 year of treatment in a retrospective study. Methods: Peripheral blood lymphocyte subsets were analyzed by flow cytometry. Untreated MS patients ( n = 40) were compared to those 6 months after onset of DMF treatment ( n = 51). Clinical and magnetic resonance imaging (MRI) disease activity of DMF-treated patients were assessed in the first year un…

AdultMale0301 basic medicineTreatment responseMultiple SclerosisAdolescentDimethyl FumarateAntigens CD19CD4-CD8 RatioCD8-Positive T-LymphocytesPharmacologyStatistics NonparametricReduction (complexity)Young Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineText miningLymphopeniamedicineHumansCytotoxic T cellLongitudinal StudiesLymphocyte CountClinical efficacyRetrospective StudiesB-LymphocytesDimethyl fumarateChemistrybusiness.industryMultiple sclerosisMiddle AgedFlow Cytometrymedicine.diseaseMagnetic Resonance ImagingCross-Sectional StudiesTreatment Outcome030104 developmental biologyROC CurveNeurologyDisease ProgressionFemaleNeurology (clinical)businessImmunosuppressive Agents030217 neurology & neurosurgeryFollow-Up StudiesLymphocyte subsetsMultiple Sclerosis Journal
researchProduct

Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis

2015

Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti-apoptotic action, with potential neuroprotective activity. A proof of principle approach was adopted to provide preliminary data regarding the efficacy and tolerability of TUDCA in a series of patients with amyotrophic lateral sclerosis (ALS). Methods: As a proof of principle, using a double-blind placebo controlled design, 34 ALS patients under treatment with riluzole who were randomized to placebo or TUDCA (1 g twice daily for 54 weeks) were e…

AdultMale0301 basic medicineamyotrophic lateral sclerosismedicine.medical_specialtyALS - TUDCA - clinical trialmedicine.drug_classPilot ProjectsAmyotrophic lateral sclerosis; Cholic acids; Tauroursodeoxycholic acid; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Drug Therapy Combination; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Pilot Projects; Riluzole; Taurochenodeoxycholic Acid; Outcome Assessment (Health Care); Neurology; Neurology (clinical)PlaceboNeuroprotectionGastroenterologyTaurochenodeoxycholic AcidOutcome Assessment (Health Care)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodDrug TherapyInternal medicinemedicineCholic acidHumansAmyotrophic lateral sclerosisAdverse effectAmyotrophic lateral sclerosiAgedtauroursodeoxycholic acidRiluzoleBile acidbusiness.industryTauroursodeoxycholic acidMiddle Agedmedicine.diseaseRiluzoleSurgerySettore MED/26 - NEUROLOGIANeuroprotective Agentscholic acids030104 developmental biologyNeurologychemistryTolerabilityCombinationFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugEuropean Journal of Neurology
researchProduct

Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine

2017

Purpose To investigate the effect of cyclosporine on corneal ultrastructure and on major signs and symptoms of patients with dry eye disease.Patients and methods In this prospective cohort study, patients with dry eye disease were treated with a drop of cyclosporine 0.05% twice daily. Clinical evaluation was carried out at baseline and at months 1, 3, and 6. All patients completed the Ocular Surface Disease Index (OSDI) questionnaire, and tear film break-up time (BUT), fluorescein and lissamine green staining, and Schirmer test were carried out. In vivo confocal microscopy was also performed and epithelial cellular density, keratocyte activation, and subbasal plexus morphology were assessed…

AdultMale0301 basic medicinemedicine.medical_specialtyAdministration TopicalConfocalDry Eye SyndromesGlaucomaCell CountOphthalmic SolutionFollow-Up StudieCorneaImmunosuppressive Agent03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOphthalmologyCorneamedicineOcular Surface Disease IndexFluoresceinProspective cohort studyAgedMicroscopy Confocalbusiness.industryMiddle Agedmedicine.diseaseStainingProspective StudieOphthalmologyTreatment Outcome030104 developmental biologymedicine.anatomical_structureNerve FiberchemistryCyclosporine030221 ophthalmology & optometryFemalebusinessDry Eye SyndromeHumanEye
researchProduct

A manual therapy and home stretching program in patients with primary frozen shoulder contracture syndrome : a case series

2019

Abstract: Background Manual therapy has been demonstrated to reduce pain and improve function in patients with frozen shoulder contracture syndrome (FSCS), but no evidence exists to support one form of manual therapy over another. The purpose of this case series was to describe both short and long-term outcomes after a manual therapy program and home stretching exercises based on specific impairments in shoulder mobility and level of tissue irritability in patients with FSCS. Case Description Eleven patients with primary FSCS were treated with an individually tailored multimodal manual therapy approach once weekly for 12 visits coupled with home stretching exercises once a day, five days pe…

AdultMale0301 basic medicinemedicine.medical_specialtyEconomicsPainMobilizationPhysical Therapy Sports Therapy and RehabilitationCASE SERIES03 medical and health sciences0302 clinical medicineSociologyBursitisShoulder PainMuscle Stretching ExercisesmedicineHumansIn patientMuscle StrengthRange of Motion Articularbusiness.industryFrozen shoulderFrozen shoulderGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyMusculoskeletal ManipulationsSurgeryTreatment Outcome030104 developmental biologymanipulationFemaleSelf ReportHuman medicineContracturemedicine.symptomManual therapybusiness030217 neurology & neurosurgeryJournal of orthopaedic & sports physical therapy
researchProduct

Application of tRNS to improve multiple sclerosis fatigue: a pilot, single-blind, sham-controlled study

2019

We evaluated the effects of transcranial random noise stimulation (tRNS) on fatigue in 17 subjects with relapsing–remitting multiple sclerosis with low physical disability. Two different patient groups underwent real or sham stimulation for 10 days, targeting the primary motor cortex of the dominant side or contralateral to the most compromised limb. In the ‘real group’, beneficial effects were observed using the Modified Fatigue Impact Scale (p = 0.04; physical subscale: p = 0.03), the subscales ‘change in health’ (p = 0.006) and ‘role limitations due to physical problems’ (p = 0.001) of the Multiple Sclerosis Quality of Life-54, and by assessing the patient impression of perceived fatigue…

AdultMale0301 basic medicinemedicine.medical_specialtyPhysical disabilityNeurologyFatigue treatmentStimulationTranscranial Direct Current StimulationSeverity of Illness IndexPlacebosYoung Adult03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicinePhysical medicine and rehabilitationOutcome Assessment Health CaremedicineHumansMultiple sclerosiSingle-Blind MethodBeneficial effectsFatigueBiological Psychiatrybusiness.industryMSQoL-54Multiple sclerosisMotor CortextRNSmedicine.diseaseFatigue impact scalePsychiatry and Mental health030104 developmental biologyPrimary motor areaNeurologyQuality of LifeFemaleMFISNeurology (clinical)Single blindPrimary motor cortexbusiness030217 neurology & neurosurgeryJournal of Neural Transmission
researchProduct